EIGR Eiger BioPharmaceuticals, Inc.

6.90
-0.10  -1%
Previous Close 7.00
Open 6.95
Price To book 1.90
Market Cap 57.73M
Shares 8,367,000
Volume 28,119
Short Ratio 5.82
Av. Daily Volume 44,710

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data to be presented at ADA meeting in 9-13, 2017. Exact date TBC. Completion of PK study 3Q 2017. Phase 2 - 28-day study initiation due 4Q 2017 data 1H 2018.
Subcutaneous exendin - MAD study
Post-Bariatric Hypoglycemia (PBH)
Phase 2 dosing commenced October 2016. Interim data due at AASLD, October 20 -24, 2017.
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
Phase 2 end of trial data released April 21, 2017. Meeting with FDA scheduled for 4Q 2017.
Lonafarnib - LOWR HDV
Chronic hepatitis delta virus (HDV)
Phase 2 presentation at AASLD November 14, 2016.
Lonafarnib - LOWR HDV – 4
Chronic hepatitis delta virus (HDV)
Phase 2 presentation at AASLD November 14, 2016.
Lonafarnib - LOWR HDV – 3
Chronic hepatitis delta virus (HDV)
Phase 2 initiated July 2016. Enrollment completion announced May 15, 2017 with data due 1Q 2018 at JPM Conference - January 8-11, 2018.
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2 dosing commenced July 2016. Enrollment to be completed 4Q 2017. Data due 2Q 2018.
Ubenimex - ULTRA
Secondary lymphedema
Phase 2b negative data released April 2015. Formerly CLDN pre-merger
MYDICAR - CUPID 2 Trial
Ischemic or dilated cardiomyopathy

Latest News

  1. Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
  2. Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
  3. Eiger BioPharma reports 1Q loss
  4. Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results
  5. Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago
  6. Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City
  7. Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection
  8. 2 'Swing for the Fences' Small Biotechs
  9. Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago
  10. Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017
  11. Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
  12. Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting
  13. Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
  14. Eiger BioPharmaceuticals to Present at the ROTH and Oppenheimer Investor Conferences in March 2017
  15. Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
  16. Eiger Completes $25 Million Debt Financing with Oxford Finance
  17. Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)
  18. How Five Star Quality Care, Inc. (FVE) Stacks Up Against Its Peers
  19. Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)